What are the 3 Strategic Questions that keep Big Pharma CEOs awake at night?
This blogpost was first published on the 2nd of February, 2007.
Apropos my earlier post “Who moved by Blockbuster cheese?”, we see evidence of considerable turmoil in the Big Pharma segment from the often unforeseen impact of a blockbuster drug falling off the pipeline in the very late stages of development, as experienced by Pfizer recently from the loss of Torcetrapib, as well the more publicized loss of Vioxx by Merck. (more…)
